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Abstract
The generation of the pro-inflammatory cytokines IL-6, TNF-a, and IL-1b fuel the acute phase response (APR). To maintain
body homeostasis, the increase of inflammatory proteins is resolved by acute phase proteins via presently unknown
mechanisms. Hepatocyte growth factor (HGF) is transcribed in response to IL-6. Since IL-6 production promotes the
generation of HGF and induces the APR, we posited that accumulating HGF might be a likely candidate for quelling excess
inflammation under non-pathological conditions. We sought to assess the role of HGF and how it influences the regulation
of inflammation utilizing a well-defined model of inflammatory activation, lipopolysaccharide (LPS)-stimulation of bone
marrow derived macrophages (BMM). BMM were isolated from C57BL6 mice and were stimulated with LPS in the presence
or absence of HGF. When HGF was present, there was a decrease in production of the pro-inflammatory cytokine IL-6, along
with an increase in the anti-inflammatory cytokine IL-10. Altered cytokine production correlated with an increase in
phosphorylated GSK3b, increased retention of the phosphorylated NFkB p65 subunit in the cytoplasm, and an enhanced
interaction between CBP and phospho-CREB. These changes were a direct result of signaling through the HGF receptor,
MET, as effects were reversed in the presence of a selective inhibitor of MET (SU11274) or when using BMM from
macrophage-specific conditional MET knockout mice. Combined, these data provide compelling evidence that under
normal circumstances, HGF acts to suppress the inflammatory response.
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Introduction
As a first line of defense in response to infection, tissue injury
and stress, macrophages generate the NFkB-dependent pro-
inflammatory cytokines, TNF-a, IL-1b and IL-6[1]. The expres-
sion of these pro-inflammatory cytokines serves to facilitate the
expeditious infiltration of immune cells by rapidly leading to an
increase in blood flow and permeability into capillaries. The
immune response is tightly regulated and dependent on signaling
through ligands binding to Toll-like receptors (TLRs) on the
surface of macrophages[2,3]. Receptor/ligand interaction initiates
a signaling cascade that involves the multifaceted enzyme, GSK3b
that can then further modulate NFkB activity to transition
between the generation of pro- and anti-inflammatory sig-
nals[4,5,6,7]. Although necessary and beneficial during infection
and tissue injury, the pro-inflammatory cytokine response must be
resolved in order to reset the homeostatic threshold and
subsequently repair affected tissues in the absence of excess
inflammatory mediators[8,9,10].
IL-6 induction serves a dual role in the transition between
propagation of the inflammatory response and initiation of the
APR[9]. The APR serves to reset homeostasis after the ensuing
inflammation by mediating the production of acute phase
proteins from hepatocytes[8,11,12]. These proteins include
plasminogen activator inhibitor type 1 (PAI-1) and urokinase
plasminogen activator (uPA), both of which are involved in the
regulation of hepatocyte growth factor (HGF) activity[12]. IL-6
also promotes HGF transcription and generation of the latent
protein[13,14,15]. Since IL-6 production both promotes the
increased generation of HGF and induces the APR, we
hypothesized that accumulating HGF may act to resolve
inflammation after stress.
To investigate this hypothesis we sought to assess the role of
HGF and its cognate receptor, MET, with regard to innate
immune activation of LPS-stimulated BMM. Our results demon-
strate that in the presence of HGF there is a significant decrease in
the secreted levels of IL-6, suggesting that HGF suppresses
inflammation after injury. The suppression of IL-6 is achieved
through HGF-dependent inactivation of GSK3b, a powerful
governor of inflammatory signaling. This inactivation of GSK3b
enhances the anti-inflammatory pathway by promoting the
interaction of phospho-CREB with CBP and, occurs in concert
with an overall decrease of phospho-p65 (Ser 276) and elevated
levels of the anti-inflammatory cytokine IL-10[16,17,18,19,20].
Hence, our results indicate that HGF is a potent anti-inflamma-
tory agent.
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e15384Results
HGF suppresses inflammation in bone marrow-derived
macrophages
In order to determine that HGF plays a role in regulating the
APR to suppress inflammation, we utilized a well-defined in vitro
model of acute inflammation: LPS stimulation of BMM. BMM
were cultured with various physiological concentrations of HGF
and then stimulated with LPS. Figure 1 demonstrates that 10 pg
and 10 ng of HGF exhibit a significant suppression of IL-6
production in LPS-stimulated BMM after 24 hours.
Pharmacological inhibition of HGF-MET signaling
abolished HGF’s suppressive effects in BMM
To further confirm that the inhibition of IL-6 production was a
result of HGF signaling, we repeated the in vitro model of acute
inflammation, this time in the presence of SU11274, a specific
MET inhibitor. An optimal concentration of 1 mM was chosen for
the inhibition of signaling in BMM. SU11274[21,22] was added to
BMM cultures 2 hr prior to the addition of HGF and then cultures
were stimulated with LPS. The results demonstrate that
incubation with the MET inhibitor abolished the inhibitory effect
induced by HGF on IL-6 production in BMM stimulated with
LPS (Figure 2).
Conditional deletion of MET-receptor on BMM confirms
pharmacological data demonstrating HGF’s suppressive
effects in BMM
To rule out any offsite pharmacological effects by the MET
inhibitor as the cause for the IL-6 inhibition and to further study
the important role HGF plays in tempering the acute inflamma-
tory response, conditional MET flox mice specific for the
macrophage lineage were generated. Figure 3 demonstrates that
BMM isolated from MET conditional knockout mice fail to
suppress IL-6 production in response to LPS as compared to their
wild type littermate controls. Use of the knockout animals
confirmed the results demonstrated with the pharmacological
MET inhibitor whereby the suppressive effect of HGF on IL-6
production was significantly reduced as compared with cultures
not treated with the inhibitor (Figure 2). Taken together, these
results clearly illustrate the interaction of HGF and MET
suppresses IL-6, further supporting the important role HGF plays
in tempering the acute inflammatory response.
HGF suppresses inflammation through GSK3b
To further understand the mechanism in which HGF suppresses
the inflammatory response, we looked downstream of HGF-MET
signaling at potential regulatory targets. One target, GSK3b,i s
Figure 1. HGF modulates IL-6 production in LPS stimulated
macrophages. BMM derived from C57BL6 mice were pretreated with
or without 10 pg and 10 ng HGF for 24 hours and stimulated with
1 mg/ml LPS. Cell culture media was collected (24 h) and IL-6 levels
were measured by ELISA. Results are representative of the mean (6
SEM) of three independent experiment done in triplicate, * indicates
,0.001.
doi:10.1371/journal.pone.0015384.g001
Figure 2. A MET kinase inhibitor abrogates HGF suppression of
IL-6. Using an optimal dose of the MET inhibitor SU11274 (1 mg), BMM
were pretreated for 2 hours before an overnight incubation with 10 and
100 pg HGF and 24 hour stimulation with LPS. Results are represen-
tative of the mean (6 SEM) of three independent experiments done in
triplicate. *, p=0.02 vs. the respective control group.
doi:10.1371/journal.pone.0015384.g002
Figure 3. Deletion of the HGF receptor MET demonstrates a
reversal in the effects of HGF on LPS stimulated BMM. BMM
derived from either macrophage specific MET conditional knockout
mice (MET
fl/fl:cre
lysZ+/2) or their wild type littermate controls (MET
fl/fl:
cre
lysZ2/2) were pretreated with or without 1, 10 and 100 pg HGF for
24 hours and stimulated with 1 mg/ml LPS. Cell culture media was
collected (24 h) and IL-6 levels were measured by ELISA. Results are
representative of two independent experiments done in triplicate.
doi:10.1371/journal.pone.0015384.g003
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resulting in pro-inflammatory cytokine production[5,7,23,24,25,26].
When GSK3b is in its inactive state (phosphorylated), its influence
over NFkB activation is limited and therefore pro-inflammatory
cytokine production is quantitatively lessened[5]. GSK3b is known
to be a downstream target of HGF[27,28,29]. We found that protein
lysates prepared from BMM isolated from C57BL6 mice cultured
with 10 ng HGF demonstrated an increased in phosphorylated, or
inactive GSK3b (Figure 4), supporting the idea that HGF-MET
interactions lead to inactivation of GSK3b.
HGF signaling leads to the interaction of CBP with
phospho-CREB by GSK3b
To further determine the downstream signaling that results
from HGF’s regulation of GSK3b, we investigated the interaction
of NFkB with the co-activator protein (CBP). Interactions between
NFkB and CBP are facilitated by activated GSK3b when there is
promotion of pro-inflammatory cytokine production[7,24]. Our
data, however, shows that the inhibition of GSK3b following HGF
treatment is associated with an increased interaction between CBP
and phospho-CREB. Stimulation of BMM with LPS in the
presence of HGF led to an increase of phosphorylated (inactive)
GSK3b (Ser 9) (Figure 4), which correlated with an increase in
CBP-phospho-CREB (Ser 133) interaction (Figure 5A) followed by
an increase in the levels of IL-10 production (Figure 5C).
HGF inhibits the phosphorylation of Ser 276 on p65 of
NFkB
The enhanced interaction between CBP and phospho-CREB
during the HGF-induced anti-inflammatory response suggests
CBP is being sequestered away from NFkB. Normally, the
transcriptional activity of NFkB occurs through the phosphoryla-
tion of p65 at Serine 276 whereby a conformational change takes
place that allows its nuclear association with CBP/p300[30]. This
interaction allows for NFkB-dependent transcription of pro-
inflammatory cytokines such as IL-6. Figure 6 demonstrates
abundant phosphorylation of p65 at Ser 276 in both the nucleus
and cytoplasm upon stimulation with LPS alone (Figure 6B).
However, with the addition of HGF (10 pg) the overall
phosphorylation of p65 is reduced with nuclear localization
essentially absent (Figure 6C). Again, the effects of HGF are
abrogated when SU11274 is added to the cultures, indicating the
suppression is mediated via the HGF receptor, MET (Figure 6D).
Discussion
IL-6, a key pro-inflammatory cytokine, is upregulated ‘‘as a
defense mechanism’’ in order to promote the APR and to initiate
homeostasis as quickly as possible after an acute injury. In cases of
chronic stress; however, IL-6 changes its role by modulating the
leukocytic repertoire resulting in a chronic inflammatory
state[9,11]. Although the presence of IL-6 is imperative during
early injury and acute inflammation, contraction of the inflam-
matory process must occur in order for the system to regain
normal homeostasis and to initiate repair. As a result, IL-6 is also
posited to possess anti-inflammatory properties. Evidence to
support this latter hypothesis is shown by the enhanced
inflammatory responses induced following endotoxin exposure to
IL-6
2/2 mice[9], although, the authors never suggest a biochem-
ical mechanism to explain why this unanticipated phenomenon
occurs. HGF, a cytokine widely known for perpetuating liver
regeneration, has also been described as having anti-inflammatory
properties in cases of persistent inflammation[27,28,29,31,32,33].
Importantly, the expression of HGF is induced by IL-6 while its
regulation is controlled via acute phase proteins (urokinase and
PAI-1) that are also induced following IL-6 stimulation. Hence, we
posited a feedback loop wherein the pro-inflammatory properties
ascribed to IL-6 are exhibited through induction of the APR and
the anti-inflammatory properties are mediated via HGF that is
produced in response to IL-6 stimulation.
Using LPS stimulated primary BMM cell cultures as a source of
IL-6, we demonstrate that addition of HGF is in fact anti-
inflammatory (Figure 1). Furthermore, we are able to confirm that
the HGF-MET interaction propagates the suppression of cytokine
production by using the pharmacological inhibitor of MET,
SU11274 (Figure 2). Other studies have focused on using
inhibitors of the PI3K and Akt signaling cascade[4,7], that are
down-stream of HGF-MET signaling; however, by using a direct
MET kinase inhibitor as well as the macrophage specific MET
floxed mice (Figure 3), we demonstrate that HGF-MET signaling
is capable of suppressing inflammation.
Traditionally, GSK3b is known for regulating glycogen
synthase and the storage of glycogen into peripheral sites[34,35],
but recent evidence suggests this kinase may also function as a key
player in modulating inflammation[7,17]. It is well known that the
activation of NFkB through TLR signaling leads to the
transcription of pro-inflammatory cytokines; however, recently
data was published indicating that at a more general level,
cytokine production is regulated through GSK3b, which in turn
regulates NFkB activity[4,7]. Hence, GSK3b appears to be a
pivotal kinase that serves as a nodal point for both the generation
and resolution of the inflammatory response[17,27,28]. Our data
demonstrates that treatment BMM with HGF leads to increased
phosphorylation and inactivation of GSK3b (Ser 9) (Figure 4) and
that this response is sustained, even in the presence of LPS.
Pharmacological inhibitors of PI3K, Akt, and GSK3b induce
inactivation of GSK3b. Inactive GSK3b can then promote the
association of phospho-CREB (Ser 133) with CBP and sequester
Figure 4. Treatment with HGF leads to increased GSK3b
phosphorylation. (A) Cytoplasmic lysates prepared from BMM were
incubated with 10 ng HGF for 24 hours prior to stimulation with LPS
(1 mg/ml) for 15 minutes. The lysates were separated by SDS-PAGE and
probed with a phospho-specific GSK3b antibody before re-probing for
b-actin. (B) Densitometric analysis for phospho-GSK3b fold induction
normalized to b-actin is shown for 3 separate experiments. Note that all
experiments show induction greater than 1 when HGF is present.
doi:10.1371/journal.pone.0015384.g004
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are associated with a switch from a pro- to anti-inflammatory
pathway with a resultant increase in IL-10 production[7]. Our
data shows that using HGF in place of those inhibitors gives
similar results. BMM treated with both LPS and HGF
demonstrated an increased CBP-phospho-CREB interaction,
which was reduced in the presence of the MET kinase inhibitor
(Figure 5). Furthermore, there was an increase in the production of
IL-10 (Figure 5C) and, a reduction in the nuclear translocation
phosphorylated p65. Combined, the data suggest that during an
inflammatory response, active HGF may be key in switching the
cellular response from a pro- to an anti-inflammatory pathway.
In addition to the canonical pathway, TLR signaling has been
shown to weakly activate PI3K. This then leads to anti-
inflammatory events by altering the cytokine repertoire[7]. Hence,
it has been postulated that PI3K is the point at which TLR
signaling is differentiated from a pro-inflammatory to an anti-
inflammatory condition. Our data indicates that in the absence of
Figure 5. HGF promotes the interaction of phosphorylated CREB with CBP along with an increased production of IL-10. (A) Whole cell
lysates prepared from BMM were incubated overnight with HGF (10 ng) prior to stimulation LPS (1 mg/ml) for 15 minutes, then subjected to
immunoprecipitation with a CBP antibody. The lysates were separated by SDS-PAGE and probed with a phospho-specific CREB antibody before re-
probing for b-actin. (B) Densitometric analysis for phospho-CREB fold induction normalized to b-actin. Is shown for 3 separate experiments. Note that
all experiments show induction greater than 1 when HGF is present. (C) BMM were pretreated with or without 1 mM of the MET kinase inhibitor
(SU11274) for 2 h prior to incubation with HGF (1, 10 and 100 pg) for 24 hours followed by stimulation with 1 mg/ml LPS. Cell culture media was
collected (24 h) and IL-10 levels were measured by ELISA. Results are representative of two independent experiments done in triplicate.
doi:10.1371/journal.pone.0015384.g005
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along with its translocation to the nucleus and that this correlates
with the production of the pro-inflammatory cytokine IL-6. In
contrast, in the presence of HGF, GSK3b is phosphorylated
(inactive) and TLR stimulation leads to production of the anti-
inflammatory cytokine, IL-10. Notably, HGF signaling is well
known to signal through the PI3K pathway[26,27,28,36]. Hence,
we propose that under normal circumstances, induction of IL-6
through pro-inflammatory stimuli leads to the eventual production
of HGF[14,15,37]. HGF-MET interactions then ultimately result
in phosphorylation of GSK3b and in the continued presence pro-
inflammatory stimuli, facilitates an increased association of
phospho-CREB with CBP. This then suppresses NFkB’s tran-
scriptional activity and results in the resolution of the inflamma-
tory response (Figure 7). Our data describe the intimate
interaction between IL-6 and HGF in regulation of inflammation.
Hence we propose that HGF acts as an internal rheostat regulating
the complex cascade of induction and resolution of inflammation
(Figure 7).
Materials and Methods
Mouse strains
C57BL/6J and B6.129P2-Lyz2
tm1(cre)Ifo/J mice were purchased
from The Jackson Laboratory and the MET floxed mice were a
gift from Dr. Snorri Thorgeirsson[38]. B6.129P2-Lyz2
tm1(cre)Ifo/J
were crossed with MET floxed mice to produce CRE
lysZ+ MET
+/+
animals. Male mice 6–8 week of age were used as a source of bone
marrow-derived macrophages. All animals were housed under
specific pathogen-free conditions in the Animal Facility at the
University of Pittsburgh. This study was carried out in strict
accordance with the recommendations in the Guide for the Care
Figure 6. HGF prevents the nuclear translocation of phosphorylated p65. BMM were (A) untreated (B) stimulated with LPS (1 mg/ml) (C)
treated with 10 pg HGF and stimulated with LPS (1 mg/ml) or (D) treated with the MET kinase inhibitor, SU11274, 10 pg HGF and stimulated with LPS
(1 mg/ml). Cytospin preparations were then stained by immunoflourescence for phosphorylated p65 (Ser 276) and for nuclei with DAPI. The blue
staining indicates nuclei, red staining indicates phosphorylated p65, and purple staining indicates colocalization of phospho-p65 within the nucleus.
doi:10.1371/journal.pone.0015384.g006
Figure 7. Proposed mechanism of HGF-mediated suppression. The canonical signaling pathway of LPS-TLR engagement leads to NFkB
dependent pro-inflammatory cytokine production through the interaction of CBP with NFkB. However, TLR signaling has also been shown to weakly
activate alternative signaling through PI3K, resulting in phosphorylation and inactivation of GSK3b, subsequent sequestration of CBP from NFkBt o
phospho-CREB, and resultant anti-inflammatory (IL-10) production[7]. Our results show that the presence of HGF enhances the IL-10 pathway. We
postulate that in order to resolve inflammation, the generation of IL-6 by LPS-TLR signaling leads to the production of HGF, ultimately leading to the
inhibition of inflammation. Hence, we propose HGF acts as an internal rheostat for resolving acute phase inflammatory responses.
doi:10.1371/journal.pone.0015384.g007
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Health. The protocol was approved by the Institutional Animal
Care and Use Committee of the University of Pittsburgh
(Assurance Number A3187-01).
Isolation of mouse bone marrow derived macrophages
Bone marrow derived macrophages (BMM) were cultured as
previously described[39]. Femurs and tibias were dissected from
sacrificed mice. Bone marrow cells were flushed from the bones
using a 26 g needle until the bone is clear. The cells were then
centrifuged and filtered through a cell strainer. Cells were cultured
in 10% L929 conditioned media, with a media change every two
days. Cultured cells were harvested and stained with the
macrophage specific marker F4/80 to assess purity 7 days after
isolation. Cells were plated on 24-well tissue culture plates at
1610
6 cells/well for supernatant analysis or on 100 cm tissue
dishes at 2.5610
7 cells/dish for protein analysis.
Preparation of samples for ELISA
BMM plated in 24-well plates were pretreated with recombi-
nant mouse HGF (R&D Systems) for 24 h at 37uC prior to
stimulation with 1 mg/ml lipopolysacharride (LPS) from Escherichia
coli (055:B5) (Sigma Aldrich) for 24 h. In assays using the MET
kinase inhibitor, SU11274 (Calbiochem), BMM were pretreated
with 1 mM of the inhibitor for 2 h at 37uC followed by the 24 h
HGF incubation and subsequent LPS stimulation. Cell culture
supernatants were collected from triplicate wells, pooled and
stored at 220uC for further analysis.
Preparation of protein lysates
BMM were prepared as above and cultured in 100 mm dishes.
At 15 minutes post-LPS stimulation, the BMM were washed with
ice cold PBS and cells were harvested with gentle scraping and
centrifugation. Cellular extracts were harvested using RIPA buffer
supplemented with phosphatase and protease inhibitor cocktails
(Roche) and 1 mM PMSF (Sigma-Aldrich). After the addition of
0.3 ml of lysis buffer, the macrophages were incubated on ice for
20 min, vortexed 3 times and centrifuged for 5 min at maximum
speed at 4uC. The supernatant (whole cell lysate) was collected and
the protein concentration of the lysates was determined by the
bicinchonninic acid (BCA) protein assay according to the
manufacturer’s instruction (Pierce).
Enzyme linked immunosorbent assay (ELISA)
Supernatants from BMM pretreated with HGF and/or
SU11274 and stimulation with LPS were collected at 24 h. IL-6
and IL-10 cytokines secreted by BMM were measured by ELISA
using purified capture and biotinylated detection antibody pairs
(BD Pharmingen). The ELISA plates were read using a
SpectraMax M2 plate reader, and the data was analyzed using
SoftMax Pro software (Molecular Devices).
Western immunoblotting
Protein lysates were assayed by Western blot as previously
described, with minor exceptions[39]. Anti-phospho-GSK3b (Ser
9), anti-phospho-CREB (Ser 133) and anti-CREB used at 1:1000
from Cell Signaling. Anti-GSK3b was used at 1:1000 from Santa
Cruz. Secondary antibodies were used from either Cell Signaling
or Jackson ImmunoResearch. Blots were analyzed using the
Fujifilm LAS-4000 imager and Multi Gauge software (Fujifilm Life
Science).
Immunoprecipitation
1 mg of CBP antibody (Santa Cruz) was added to 100 mg
protein from whole cell lysates and incubated at 4uC overnight.
The following day, Protein G-conjugated sepharose beads were
added to the protein/antibody complex tube and incubated for
2 h. Immunoprecipitates were collected by centrifugation, washed
twice with PBS, and then boiled in Laemmli sample buffer.
Western blot was performed as described above.
Cytospins
BMMs were washed with PBS and gently scraped from multi-
well tissue culture dishes. Cells were collected into centrifuge tubes
and spun at high speed for 10 min. Cell pellets were resuspended
to 1610
3 cells per ml and cytospins were prepared with 100 mlo f
cells per slide. Slides were dried and stored at 280uC until
staining.
Phospho-NFkB p65 (Ser276) staining
Cytospun slides were fixed in 2% paraformaldehyde for 5
minutes and blocked with 20% non-immune normal goat serum
for 1 hour at room temperature. After immune stained with
primary antibody (Rabbit anti-Phospho-NFkBp65 (Ser276) 1:100,
(Cell Signaling Technology), slides were washed 5 times in PBS
and incubated with secondary antibodies Cy3-conjugated goat
anti-rabbit (Jackson ImmunoResearch). Nuclear staining (Hoech-
est staining, Molecular Probes) was performed. Images were
viewed at 40x magnification and captured by using a Nikon
confocal microscope (Nikon D-ECLIPSE C1, Japan).
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